Potential Canonical Wnt Pathway Activation in High-Grade Astrocytomas

Table 2

Clinicopathological characteristics of patients included in TMA analysis.

Histological diagnosis		Patients
		𝑛=283 (%)
Glioblastoma	WHO IV	221 (78.1)
Anaplastic astrocytoma	WHO III	17 (6.0)
Diffuse astrocytoma	WHO II	45 (15.9)
Age		mean (𝑦) ± SD
Glioblastoma	WHO IV	53.8 ± 12.8
Anaplastic astrocytoma	WHO III	36.1 ± 14.2
Diffuse astrocytoma	WHO II	33.6 ± 18.7
Gender		M : F
Glioblastoma	WHO IV	133 : 88
Anaplastic astrocytoma	WHO III	11 : 6
Diffuse astrocytoma	WHO II	30 : 15
Extent of resection		Total	Subtotal/biopsy
		𝑛 = (%)	𝑛 = (%)
Glioblastoma	WHO IV	151 (68.3)	70 (31.7)
Anaplastic astrocytoma	WHO III	11 (64.7)	6 (35.3)
Diffuse astrocytoma	WHO II	33 (73.3)	12 (26.7)
Adjuvant treatment^†		Radiotherapy	Chemotherapy
		𝑛 = (%)	𝑛 = (%)
Glioblastoma	WHO IV	186 (84.2)	87 (39.4)
Anaplastic astrocytoma	WHO III	16 (94.1)	1 (5.9)
Diffuse astrocytoma	WHO II	14 (31.1)	3 (6.7)

^†Therapy at primary tumour diagnosis.